PYRROLIDINE DERIVATIVES AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS
申请人:Bissantz Caterina
公开号:US20080275021A1
公开(公告)日:2008-11-06
The invention relates to pyrrolidine derivatives of formula
wherein
R
1
,
R
2
,
R
3
,
n, and o are defined in the specification and to pharmaceutically active acid-addition salts thereof. Compounds of formula I have a high affinity simultaneously to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor antagonists), useful in the treatment of schizophrenia.
This invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as Via receptor antagonists and which are represented by Formula I:
wherein the spiropiperidine-head group A and the residues R
1
, R
2
and R
3
are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and to methods of preparation thereof.
Present invention is concerned with novel indol-2-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them. The active compounds of the present invention are useful in the treatment of anxiety and depressive disorders and other diseases. The compounds of present invention have the general formula (I)
wherein R
1
to R
11
and X are as defined in the description.